en · de · es · fr · pt
thymosin-alpha-1-notes.peptides9002.com › Info › Molecular Identity Of Thymosin Alpha-1 — Deep Dive

Molecular Identity Of Thymosin Alpha-1 — Deep Dive

By Editorial Desk · published 2026-02-07 · last reviewed 2026-03-28 · Info

systematic review is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.

Molecular Identity Of Thymosin Alpha-1

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Background and Molecular Identity

The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.

Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.

Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.

Thymosin-alpha-1 at a glance

PropertyValueNotes
ClassSynthetic peptide28 residues; not a small-molecule compound
Molecular massAbout 3,106 DaMonoisotopic mass of the unmodified chain
N-terminal groupAcetylated serinePresent in both native and synthetic forms
Secondary structureDisulfide-constrained loopOne bridge between two cysteine residues
Typical sourceSolid-phase synthesisEarly isolates came from bovine thymus extracts

Background and Molecular Profile

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

Related pages on this site

Handling, Storage, and Analytical Verification

Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.

Research History and Clinical Assessment

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Background, Structure, and Mechanism

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Notes from published material

A GGT test is predominantly used as a diagnostic marker for liver disease. Elevated serum GGT activity can be found in diseases of the liver, biliary system, pancreas and kidneys. Latent elevations in GGT are typically seen in patients with chronic viral hepatitis infections often taking 12 months or more to present. Individual test results should always be interpreted using the reference range from the laboratory that performed the test, though example reference ranges are 15–85 IU/L for men, and 5–55 IU/L for women. GGT is similar to alkaline phosphatase (ALP) in detecting disease of the biliary tract. Indeed, the two markers correlate well, though there are conflicting data about whether GGT has better sensitivity. In general, ALP is still the first test for biliary disease. The main value of GGT is in verifying that ALP elevations are, in fact, due to biliary disease; ALP can also be increased in certain bone diseases, but GGT is not.

Electrochemotherapy is the combined treatment in which injection of a chemotherapeutic drug is followed by application of high-voltage electric pulses locally to the tumor. The treatment enables the chemotherapeutic drugs, which otherwise cannot or hardly go through the membrane of cells (such as bleomycin and cisplatin), to enter the cancer cells. Hence, greater effectiveness of antitumor treatment is achieved. Clinical electrochemotherapy has been successfully used for treatment of cutaneous and subcutaneous tumors irrespective of their histological origin. The method has been reported as safe, simple and highly effective in all reports on clinical use of electrochemotherapy. According to the ESOPE project (European Standard Operating Procedures of Electrochemotherapy), the Standard Operating Procedures (SOP) for electrochemotherapy were prepared, based on the experience of the leading European cancer centres on electrochemotherapy. Recently, new electrochemotherapy modalities have been developed for treatment of internal tumors using surgical procedures, endoscopic routes or percutaneous approaches to gain access to the treatment area.

==== Positive ion formation ==== Once the metastable carrier gas atoms (M*) released from the source, they initiate Penning ionization of nitrogen, atmospheric water and other gaseous species. Although some compounds can be ionized directly by Penning ionization, the most common positive-ion formation mechanism for DART involves ionization of atmospheric water.

== Pharmaceuticals == The vaccine vial monitors are a family of TTIs used by the World Health Organization to track the degradation of vaccines. This is important as many places in the world do not have a reliable cold chain and vaccines tend to spend some time not refrigerated. Based on data on how long a vaccine stays useful at different temperatures, a VVM that matches the vaccine's degradation behavior is chosen. The VVM takes into account all heat exposures except for small peaks. TTIs are also used to protect other heat-sensitive drugs, many of which are complex biologics. Vaccines are a kind of biologics.

Sources: en.wikipedia.org

Background from the literature

=== Economic Sciences === The medal for the Nobel Memorial Prize in Economic Sciences was designed by Gunvor Svensson-Lundqvist in 1968. The obverse of the medal depicts Alfred Nobel and the words "Sveriges Riksbank till Alfred Nobels Minne 1968" ("The Sveriges Riksbank, in memory of Alfred Nobel, 1968") with the symbol of the Sveriges Riksbank, the horn of plenty, displayed below. The name of the recipient is inscribed on the edge of the medal. The reverse features the emblem of the Royal Swedish Academy of Sciences, the North Star, in a design from 1815. "Kungliga Vetenskaps Akademien" ("The Royal Swedish Academy of Sciences") is inscribed around the edge of the star. It is the only medal without a quotation on its reverse. Since 2012 the economics medal has been manufactured by Svenska Medalj in Eskilstuna.

Lipton Iced Tea or Lipton Ice Tea a ready to drink tea brand made and distributed by the joint ventures between Unilever and PepsiCo. It is typically sold in five flavours, lemon, peach, mint & lime, mango, and raspberry. Citrus, watermelon, and mixed berry flavours are also available in some regions.

==== Insulin ==== In October 1920, Frederick Banting took interest in carbohydrate metabolism while preparing a talk he was to give his physiology students at Western University in London, Ontario. He encountered an article by Moses Barron which reported an autopsy of a patient whose pancreatic stone had obstructed the main pancreatic duct, but most of the islet cells had survived intact. Banting wrote a note on October 31 of that year describing his thinking: "Ligate pancreatic ducts of dog. Keep dogs alive till acini degenerate leaving Islets. Try to isolate the internal secretion of these to relieve glycosurea [sic]" On November 8, 1920, Banting met with John Macleod, a senior professor of physiology at the University of Toronto, to ask if he might mount a research project on the internal secretion of the pancreas. Banting lacked experience in physiological research and had superficial knowledge of the subject. Nonetheless, Macleod took some interest and accepted Banting's request to work in his lab. On account of what may have interested Macleod, Michael Bliss considers the following:Speculation is in order here and is permissible because we have some idea of Macleod's knowledge of the literature. Whether he and Banting were discussing grafting or extracting, what must have appealed to Macleod as "never having been tried before" was the idea of somebody experimenting with degenerated or atrophied pancreas.

== F == fat redistribution – FDA FDC – floaters – follicle – follicular dendritic cells (FDCs) – Food and Drug Administration (United States) functional antibody – fungus – fusin – fusion inhibitor – fusion mechanism – fusion peptide

=== Mechanism of action === Dupilumab binds to the alpha subunit of the interleukin-4 receptor (IL-4Rα), making it a receptor antagonist. Through blockade of IL-4Rα, dupilumab modulates signaling of both the interleukin 4 and interleukin 13 pathways.

Sources: en.wikipedia.org

Reference notes

Nejnezdevětadevadesáteroroznásobovávatelnějšími (47; Instrumental case of the ones least multipliable by a group of ninety-nine on a regular basis) Nejnezdevětadevadesáteroroznásobovávatelnější (Those who are the least multiplable by a group ninety-nine on a regular basis) Nejzdevětadevadesáteroroznásobovávatelnější (Those who are the most multiplable by a group ninety-nine on a regular basis) Zdevětadevadesáteroroznásobovávatelnější (Those who are more multiplable by a group ninety-nine on a regular basis) Zdevětadevadesáteroroznásobovávatelní (Those who are multiplable by a group of ninety-nine on a regular basis) Zdevětadevadesáteroroznásobovávat (Alternative of "multiply out by a group of ninety-nine on a regular basis") Zdevětadevadesáteroroznásobovat (Multiply out by a group of ninety-nine on a regular basis — continuous grammatical aspect) Zdevětadevadesáteroznásobovat (Multiply by ninety-nine on a regular basis – continuous grammatical aspect) Zdevětadevadesáteroznásobit (Multiply by a group of ninety-nine once) Zdevětadevadesáteronásobit (Multiply by a group of ninety-nine) Devětadevadesátero (A group of ninety-nine) Devětadevadesát (Inverse of devadesát devět = ninety-nine)

== Definition == The definition of a genetically modified organism (GMO) is not clear and varies widely between countries, international bodies, and other communities. At its broadest, the definition of a GMO can include anything that has had its genes altered, including by nature. Taking a less broad view, it can encompass every organism that has had its genes altered by humans, which would include all crops and livestock. In 1993, the Encyclopedia Britannica defined genetic engineering as "any of a wide range of techniques ... among them artificial insemination, in vitro fertilization (e.g., 'test-tube' babies), sperm banks, cloning, and gene manipulation." The European Union (EU) included a similarly broad definition in early reviews, specifically mentioning GMOs being produced by "selective breeding and other means of artificial selection" These definitions were promptly adjusted with a number of exceptions added as the result of pressure from scientific and farming communities, as well as developments in science. The EU definition later excluded traditional breeding, in vitro fertilization, induction of polyploidy, mutation breeding, and cell fusion techniques that do not use recombinant nucleic acids or a genetically modified organism in the process. Another approach was the definition provided by the Food and Agriculture Organization, the World Health Organization, and the European Commission, stating that the organisms must be altered in a way that does "not occur naturally by mating and/or natural recombination".

==== Advocacy for tolerance ==== Despite being illegal to possess without authorization in many Western countries, such as the UK, Australia, and some U.S. states, less conservative governments nurture the legal possession and supply of psilocybin and other psychedelic drugs. In Amsterdam, authorities provide education on and promote the safe use of psychedelic drugs, such as psilocybin, to reduce public harm. Similarly, religious groups like America's Uniao do Vegetal (UDV) use psychedelics in traditional ceremonies. A report from the U.S. Government Accountability Office (GAO) notes that people may petition the DEA for exemptions to use psilocybin for religious purposes. From July 1, 2023, the Australian medicines regulator has permitted psychiatrists to prescribe psilocybin for the therapeutic treatment of treatment-resistant depression. Advocates of legalization argue there is a lack of evidence of harm, and potential use in treating certain mental health conditions. Research is difficult to conduct because of the legal status of psychoactive substances. Advocates of legalization also promote the utility of "ego dissolution" and argue bans are cultural discrimination against traditional users. In 2024, after calls for regulatory and legal change to expand terminally ill populations' access to controlled substances, two legal cases related to expanded access began moving through the federal courts under right-to-try law.

Agrobacterium tumefaciens overwinters in infested soils. Agrobacterium species live predominantly saprophytic lifestyles, so its common even for plant-parasitic species of this genus to survive in the soil for lengthy periods of time, even without host plant presence. When there is a host plant present, however, the bacteria enter the plant tissue via recent wounds or natural openings of roots or stems near the ground. These wounds may be caused by cultural practices, grafting, insects, etc. Once the bacteria have entered the plant, they occur intercellularly and stimulate surrounding tissue to proliferate due to cell transformation. Agrobacterium performs this control by inserting the plasmid T-DNA into the plant's genome. See above for more details about the process of plasmid DNA insertion into the host genome. Excess growth of the plant tissue leads to gall formation on the stem and roots. These tumors exert significant pressure on the surrounding plant tissue, which causes this tissue to become crushed and/or distorted. The crushed vessels lead to reduced water flow in the xylem. Young tumors are soft and therefore vulnerable to secondary invasion by insects and saprophytic microorganisms. This secondary invasion causes the breakdown of the peripheral cell layers as well as tumor discoloration due to decay. Breakdown of the soft tissue leads to release of the Agrobacterium tumefaciens into the soil allowing it to restart the disease process with a new host plant.

Sources: en.wikipedia.org

Frequently asked questions

Is this peptide found naturally in the body?

Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.

Why is the disulfide bridge important?

The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.

How does it differ from other thymic peptides?

It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.

What is thymosin alpha-1?

It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.

Network